- cafead Mar 02, 2023 at 11:22: PM
via After several market withdrawals, the FDA’s scrutiny around the PARP inhibitor class of cancer drugs doesn't seem to be abating.
The FDA plans to gather external experts for an advisory committee meeting to review AstraZeneca and Merck & Co.’s application for Lynparza in metastatic castration-resistant prostate cancer (mCRPC), the two companies said Thursday.
article source
The FDA plans to gather external experts for an advisory committee meeting to review AstraZeneca and Merck & Co.’s application for Lynparza in metastatic castration-resistant prostate cancer (mCRPC), the two companies said Thursday.
article source